DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Graham, R. A.
Right arrow Articles by Parkinson, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Graham, R. A.
Right arrow Articles by Parkinson, A.

Vol. 30, Issue 11, 1206-1213, November 2002

In Vivo and in Vitro Induction of Cytochrome P450 Enzymes in Beagle Dogs

Richard A. Graham,1 April Downey, Dan Mudra, Linda Krueger, Kathy Carroll, Christopher Chengelis, Ajay Madan,2 and Andrew Parkinson

XenoTech, LLC, Lenexa, Kansas (R.A.G., A.D., D.M., L.K., K.C., A.M., A.P.), and WIL Research Laboratories, Inc., Ashland, Ohio (C.C.)

The aim of this study was to determine the in vitro and in vivo effects of several prototypical inducers, namely beta -naphthoflavone, 3-methylcholanthrene, phenobarbital, isoniazid, rifampin, and clofibric acid, on the expression of cytochrome P450 (P450) enzymes in beagle dogs. For the in vitro induction study, primary cultures of dog hepatocytes were treated with enzyme inducers for 3 days, after which microsomes were prepared and analyzed for P450 activities. For the in vivo induction study, male and female beagle dogs were treated with enzyme inducers for 4 days (with the exception of phenobarbital, which was given for 14 days), after which the livers were removed and microsomal P450 activities were determined ex vivo. Treatment of male beagle dog hepatocyte cultures (n = 3) with beta -naphthoflavone or 3-methlychloranthrene resulted in up to a 75-fold increase in microsomal 7-ethoxyresorufin O-dealkylase (CYP1A1/2) activity, whereas in vivo treatment of male and female beagle dogs with beta -naphthoflavone followed by ex vivo analysis resulted in up to a 24-fold increase. Phenobarbital caused a 13-fold increase in 7-benzyloxyresorufin O-dealkylase (CYP2B11) activity in vitro and up to a 9.9-fold increase in vivo. Isoniazid had little or no effect on 4-nitrophenol hydroxylase activity in vitro. Rifampin caused a 13-fold induction of testosterone 6beta -hydroxylase (CYP3A12) activity in vitro and up to a 4.5-fold increase in vivo. Treatment of dogs in vivo or dog hepatocytes in vitro with clofibric acid appeared to have no effect on CYP4A activity as determined by the 12-hydroxylation of lauric acid. In general, the absolute rates (picomoles per minute per milligram of microsomal protein) of P450 reactions catalyzed by microsomes from cultured hepatocytes (i.e., in vitro rates) were considerably lower than those catalyzed by microsomes from dog liver (i.e., ex vivo rates). These results suggest that beagle dogs have CYP1A, CYP2B, CYP2E, and CYP3A enzymes and that the induction profile resembles the profile observed in humans more than in rats.


1 Current Address: Division of Drug Delivery and Disposition, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599.

2 Current Address: Neurocrine Biosciences, Inc., 10555 Science Center Drive, San Diego, CA 92121.


Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
M. Mise, T. Hashizume, and S. Komuro
Characterization of Substrate Specificity of Dog CYP1A2 Using CYP1A2-Deficient and Wild-Type Dog Liver Microsomes
Drug Metab. Dispos., September 1, 2008; 36(9): 1903 - 1908.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
R. A. Graham, B. Goodwin, R. V. Merrihew, W. L. Krol, and E. L. LeCluyse
Cloning, Tissue Expression, and Regulation of Beagle Dog CYP4A Genes
Toxicol. Sci., August 1, 2006; 92(2): 356 - 367.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
C. R. Gibson, C. Lin, R. Singh, C. M. Brown, K. Richards, J. Brunner, K. Michel, J. Adelsberger, E. Carlini, C. Boothe-Genthe, et al.
INDUCTION OF CYP1A IN THE BEAGLE DOG BY AN INHIBITOR OF KINASE INSERT DOMAIN-CONTAINING RECEPTOR: DIFFERENTIAL EFFECTS IN VITRO AND IN VIVO ON MRNA AND FUNCTIONAL ACTIVITY
Drug Metab. Dispos., July 1, 2005; 33(7): 1044 - 1051.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
M. Mise, S. Yadera, M. Matsuda, T. Hashizume, S. Matsumoto, Y. Terauchi, and T. Fujii
POLYMORPHIC EXPRESSION OF CYP1A2 LEADING TO INTERINDIVIDUAL VARIABILITY IN METABOLISM OF A NOVEL BENZODIAZEPINE RECEPTOR PARTIAL INVERSE AGONIST IN DOGS
Drug Metab. Dispos., February 1, 2004; 32(2): 240 - 245.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.